The use of pharmacokinetics in dose individualization of factor VIII in the treatment of hemophilia A

References

• Mannucci PM, Tuddenham EG. The hemophilias–from royal genes to gene therapy. N Engl J Med. 2001;344:1773–1779.
   PubMed Web of Science ®Google Scholar
• Stonebraker JS, Bolton-Maggs PH, Soucie JM, et al. A study of variations in the reported haemophilia A prevalence around the world. Haemophilia. 2010;16:20–32.
   PubMed Web of Science ®Google Scholar
• Castro HE, Briceno MF, Casas CP, et al. The history and evolution of the clinical effectiveness of haemophilia type a treatment: a systematic review. Indian J Hematol Blood Transfus. 2014;30:1–11.
   PubMed Web of Science ®Google Scholar
• Nilsson IM, Hedner U, Ahlberg A. Haemophilia prophylaxis in Sweden. Acta Paediatr Scand. 1976;65:129–135.
   PubMed Web of Science ®Google Scholar
• Mannucci PM. AIDS, hepatitis and hemophilia in the 1980s: memoirs from an insider. J Thromb Haemost. 2003;1:2065–2069.
   PubMed Web of Science ®Google Scholar
• Lusher JM, Arkin S, Abildgaard CF, et al. Recombinant factor VIII for the treatment of previously untreated patients with hemophilia A. Safety, efficacy, and development of inhibitors. Kogenate Previously Untreated Patient Study Group. N Engl J Med. 1993;328:453–459.
   PubMed Web of Science ®Google Scholar
• Schwartz RS, Abildgaard CF, Aledort LM, et al. Human recombinant DNA-derived antihemophilic factor (factor VIII) in the treatment of hemophilia A. N Engl J Med. 1990;323:1800–1805.
   PubMed Web of Science ®Google Scholar
• Nilsson IM, Blomback M, Ramgren O. Haemophilia in Sweden. VI. Treatment of haemophilia A with the human antihaemophilic factor preparation (fraction I–0). Acta Med Scand Suppl. 1962;379:61–110.
   PubMedGoogle Scholar
• Ahlberg A. Haemophilia in Sweden. VII. Incidence, treatment and prophylaxis of arthropathy and other musculo-skeletal manifestations of haemophilia A and B. Acta Orthop Scand Suppl. 1965;36:3–132.
   PubMedGoogle Scholar
• Den Uijl IE, Mauser Bunschoten EP, Roosendaal G, et al. Clinical severity of haemophilia A: does the classification of the 1950s still stand? Haemophilia. 2011;17:849–853.
   PubMed Web of Science ®Google Scholar
• Oldenburg J. Prophylaxis in bleeding disorders. Thromb Res. 2011;127(Suppl 1):S14–S17.
   Google Scholar
• Berntorp E, Spotts G, Patrone L, et al. Advancing personalized care in hemophilia A: ten years’ experience with an advanced category antihemophilic factor prepared using a plasma/albumin-free method. Biologics. 2014;8:115–127.
   PubMedGoogle Scholar
• Fischer K, Collins PW, Ozelo MC, et al. When and how to start prophylaxis in boys with severe hemophilia without inhibitors: communication from the SSC of the ISTH. J Thromb Haemost. 2016;14:1105–1109. Accepted Article. doi:10.1111/jth.13298.
   PubMed Web of Science ®Google Scholar
• Petrini P. Identifying and overcoming barriers to prophylaxis in the management of haemophilia. Haemophilia. 2007;13(Suppl 2):16–22.
   PubMed Web of Science ®Google Scholar
• Carcao M, Srivastava A. Factor VIII/factor IX prophylaxis for severe hemophilia. Semin Hematol. 2016;53:3–9.
   PubMed Web of Science ®Google Scholar
• Manco-Johnson MJ, Abshire TC, Shapiro AD, et al. Prophylaxis versus episodic treatment to prevent joint disease in boys with severe hemophilia. N Engl J Med. 2007;357:535–544.
   PubMed Web of Science ®Google Scholar
• Ar MC, Vaide I, Berntorp E, et al. Methods for individualising factor VIII dosing in prophylaxis. Eur J Haematol Suppl. 2014;76:16–20.
   PubMedGoogle Scholar
• Bjorkman S, Berntorp E. Pharmacokinetics of coagulation factors: clinical relevance for patients with haemophilia. Clin Pharmacokinet. 2001;40:815–832.
   PubMed Web of Science ®Google Scholar
• Bjorkman S, Folkesson A, Jonsson S. Pharmacokinetics and dose requirements of factor VIII over the age range 3-74 years: a population analysis based on 50 patients with long-term prophylactic treatment for haemophilia A. Eur J Clin Pharmacol. 2009;65:989–998.
   PubMed Web of Science ®Google Scholar
• Bjorkman S, Oh M, Spotts G, et al. Population pharmacokinetics of recombinant factor VIII: the relationships of pharmacokinetics to age and body weight. Blood. 2012;119:612–618.
   PubMed Web of Science ®Google Scholar
• Morfini M. Comparative pharmacokinetic studies in haemophilia. Haemophilia. 2002;8(Suppl 2):30–33.
   PubMed Web of Science ®Google Scholar
• Wakefield J. The Bayesian analysis of population pharmacokinetic models. J Am Stat Assoc. 1996;91:62–75.
   Web of Science ®Google Scholar
• Collins PW, Bjorkman S, Fischer K, et al. Factor VIII requirement to maintain a target plasma level in the prophylactic treatment of severe hemophilia A: influences of variance in pharmacokinetics and treatment regimens. J Thromb Haemost. 2010;8:269–275.
   PubMed Web of Science ®Google Scholar
• Samara E, Granneman R. Role of population pharmacokinetics in drug development: a pharmaceutical industry perspective. Clin Pharmacokinet. 1997;32:294–312.
   PubMed Web of Science ®Google Scholar
• Ette EI, Williams PJ. Population pharmacokinetics I: background, concepts, and models. Ann Pharmacother. 2004;38:1702–1706.
   PubMed Web of Science ®Google Scholar
• Holford NH, Buclin T. Safe and effective variability-a criterion for dose individualization. Ther Drug Monit. 2012;34:565–568.
   PubMed Web of Science ®Google Scholar
• Sheiner LB, Beal S, Rosenberg B, et al. Forecasting individual pharmacokinetics. Clin Pharmacol Ther. 1979;26:294–305.
   PubMed Web of Science ®Google Scholar
• Tod MM, Padoin C, Petitjean O. Individualising aminoglycoside dosage regimens after therapeutic drug monitoring: simple or complex pharmacokinetic methods? Clin Pharmacokinet. 2001;40:803–814.
   PubMed Web of Science ®Google Scholar
• Ting LS, Villeneuve E, Ensom MH. Beyond cyclosporine: a systematic review of limited sampling strategies for other immunosuppressants. Ther Drug Monit. 2006;28:419–430.
   PubMed Web of Science ®Google Scholar
• Bjorkman S. Limited blood sampling for pharmacokinetic dose tailoring of FVIII in the prophylactic treatment of haemophilia A. Haemophilia. 2010;16:597–605.
   PubMed Web of Science ®Google Scholar
• Bjorkman S, Carlsson M. The pharmacokinetics of factor VIII and factor IX: methodology, pitfalls and applications. Haemophilia. 1997;3:1–8.
   PubMed Web of Science ®Google Scholar
• Brenner GM, Stevens CW. Pharmacokinetics. In: Pharmacology. 4th ed. Philadelphia (PA): Elsevier Saunders; 2013. p. 10.
   Google Scholar
• Deitcher SR, Tuller J, Johnson JA. Intranasal DDAVP induced increases in plasma von Willebrand factor alter the pharmacokinetics of high-purity factor VIII concentrates in severe haemophilia A patients. Haemophilia. 1999;5:88–95.
   PubMed Web of Science ®Google Scholar
• Lee CA, Owens D, Bray G, et al. Pharmacokinetics of recombinant factor VIII (recombinate) using one-stage clotting and chromogenic factor VIII assay. Thromb Haemost. 1999;82:1644–1647.
   PubMed Web of Science ®Google Scholar
• Saez A, Bosh N, Boadas N, et al. Pharmacokinetics and acute tolerance of a double virus inactivated plasma derived factor VIII concentrate. Haemophilia. 1999;5:260–265.
   PubMed Web of Science ®Google Scholar
• Abshire TC, Brackmann HH, Scharrer I, et al. Sucrose formulated recombinant human antihemophilic factor VIII is safe and efficacious for treatment of hemophilia A in home therapy–International Kogenate-FS Study Group. Thromb Haemost. 2000;83:811–816.
   PubMed Web of Science ®Google Scholar
• Powell JS, Bush M, Harrison J, et al. Safety and efficacy of solvent/detergent-treated antihaemophilic factor with an added 80 degrees C terminal dry heat treatment in patients with haemophilia A. Haemophilia. 2000;6:140–149.
   PubMed Web of Science ®Google Scholar
• Courter SG, Bedrosian CL. Clinical evaluation of B-domain deleted recombinant factor VIII in previously treated patients. Semin Hematol. 2001;38:44–51.
   PubMed Web of Science ®Google Scholar
• Rothschild C, Scharrer I, Brackmann HH, et al. European data of a clinical trial with a sucrose formulated recombinant factor VIII in previously treated haemophilia A patients. Haemophilia. 2002;8(Suppl 2):10–14.
   PubMed Web of Science ®Google Scholar
• Lusher JM, Lee CA, Kessler CM, et al. The safety and efficacy of B-domain deleted recombinant factor VIII concentrate in patients with severe haemophilia A. Haemophilia. 2003;9:38–49.
   PubMed Web of Science ®Google Scholar
• Morfini M, Cinotti S, Bellatreccia A, et al. A multicenter pharmacokinetic study of the B-domain deleted recombinant factor VIII concentrate using different assays and standards. J Thromb Haemost. 2003;1:2283–2289.
   PubMed Web of Science ®Google Scholar
• Blanchette V, Shapiro AD, Liesner R, et al. Characterization of the pharmacokinetics of rFVIII in young pre-school children with Hemophilia, including an analysis of the influence of age and body weight. Blood (ASH Annual Meeting Abstracts). 2004;104:3084.
   Web of Science ®Google Scholar
• Tarantino MD, Collins PW, Hay CR, et al. Clinical evaluation of an advanced category antihaemophilic factor prepared using a plasma/albumin-free method: pharmacokinetics, efficacy, and safety in previously treated patients with haemophilia A. Haemophilia. 2004;10:428–437.
   PubMed Web of Science ®Google Scholar
• Wolf DM, Rokicka-Milewska R, Lopaciuk S, et al. Clinical efficacy, safety and pharmacokinetic properties of the factor VIII concentrate Haemoctin SDH in previously treated patients with severe haemophilia A. Haemophilia. 2004;10:438–448.
   PubMed Web of Science ®Google Scholar
• Kessler CM, Gill JC, White GC 2nd, et al. B-domain deleted recombinant factor VIII preparations are bioequivalent to a monoclonal antibody purified plasma-derived factor VIII concentrate: a randomized, three-way crossover study. Haemophilia. 2005;11:84–91.
   PubMed Web of Science ®Google Scholar
• Di Paola J, Smith MP, Klamroth R, et al. ReFacto and advate: a single-dose, randomized, two-period crossover pharmacokinetics study in subjects with haemophilia A. Haemophilia. 2007;13:124–130.
   PubMed Web of Science ®Google Scholar
• Powell JS, Nugent DJ, Harrison JA, et al. Safety and pharmacokinetics of a recombinant factor VIII with pegylated liposomes in severe hemophilia A. J Thromb Haemost. 2008;6:277–283.
   PubMed Web of Science ®Google Scholar
• Recht M, Nemes L, Matysiak M, et al. Clinical evaluation of moroctocog alfa (AF-CC), a new generation of B-domain deleted recombinant factor VIII (BDDrFVIII) for treatment of haemophilia A: demonstration of safety, efficacy, and pharmacokinetic equivalence to full-length recombinant factor VIII. Haemophilia. 2009;15:869–880.
   PubMed Web of Science ®Google Scholar
• Santoro C, Iorio A, Ferrante F, et al. Performance of recalibrated ReFacto laboratory standard in the measurement of FVIII plasma concentration via the chromogenic and one-stage assays after infusion of recalibrated ReFacto (B-domain deleted recombinant factor VIII). Haemophilia. 2009;15:779–787.
   PubMed Web of Science ®Google Scholar
• El-Ekiaby M, Goubran HA, Radosevich M, et al. Pharmacokinetic study of minipooled solvent/detergent-filtered cryoprecipitate factor VIII. Haemophilia. 2011;17:e884–e888.
   PubMed Web of Science ®Google Scholar
• Martinowitz U, Bjerre J, Brand B, et al. Bioequivalence between two serum-free recombinant factor VIII preparations (N8 and ADVATE(R))–an open-label, sequential dosing pharmacokinetic study in patients with severe haemophilia A. Haemophilia. 2011;17:854–859.
   PubMed Web of Science ®Google Scholar
• Valentino LA, Mamonov V, Hellmann A, et al. A randomized comparison of two prophylaxis regimens and a paired comparison of on-demand and prophylaxis treatments in hemophilia A management. J Thromb Haemost. 2012;10:359–367.
   PubMed Web of Science ®Google Scholar
• Jimenez-Yuste V, Lejniece S, Klamroth R, et al. The pharmacokinetics of a B-domain truncated recombinant factor VIII, turoctocog alfa (NovoEight(R)), in patients with hemophilia A. J Thromb Haemost. 2015;13:370–379.
   PubMed Web of Science ®Google Scholar
• Powell JS, Josephson NC, Quon D, et al. Safety and prolonged activity of recombinant factor VIII Fc fusion protein in hemophilia A patients. Blood. 2012;119:3031–3037.
   PubMed Web of Science ®Google Scholar
• Coyle TE, Reding MT, Lin JC, et al. Phase I study of BAY 94-9027, a PEGylated B-domain-deleted recombinant factor VIII with an extended half-life, in subjects with hemophilia A. J Thromb Haemost. 2014;12:488–496.
   PubMed Web of Science ®Google Scholar
• Mahlangu J, Powell JS, Ragni MV, et al. Phase 3 study of recombinant factor VIII Fc fusion protein in severe hemophilia A. Blood. 2014;123:317–325.
   PubMed Web of Science ®Google Scholar
• Tiede A, Brand B, Fischer R, et al. Enhancing the pharmacokinetic properties of recombinant factor VIII: first-in-human trial of glycoPEGylated recombinant factor VIII in patients with hemophilia A. J Thromb Haemost. 2013;11:670–678.
   PubMed Web of Science ®Google Scholar
• Young G, Mahlangu J, Kulkarni R, et al. Recombinant factor VIII Fc fusion protein for the prevention and treatment of bleeding in children with severe hemophilia A. J Thromb Haemost. 2015;13:967–977.
   PubMed Web of Science ®Google Scholar
• Bjorkman S, Blanchette VS, Fischer K, et al. Comparative pharmacokinetics of plasma- and albumin-free recombinant factor VIII in children and adults: the influence of blood sampling schedule on observed age-related differences and implications for dose tailoring. J Thromb Haemost. 2010;8:730–736.
   PubMed Web of Science ®Google Scholar
• Vlot AJ, Mauser-Bunschoten EP, Zarkova AG, et al. The half-life of infused factor VIII is shorter in hemophiliac patients with blood group O than in those with blood group A. Thromb Haemost. 2000;83:65–69.
   PubMed Web of Science ®Google Scholar
• Fischer K, Pendu R, van Schooten CJ, et al. Models for prediction of factor VIII half-life in severe haemophiliacs: distinct approaches for blood group O and non-O patients. PLoS One. 2009;4:e6745.
   PubMed Web of Science ®Google Scholar
• Kepa S, Horvath B, Reitter-Pfoertner S, et al. Parameters influencing FVIII pharmacokinetics in patients with severe and moderate haemophilia A. Haemophilia. 2015;21:343–350.
   PubMed Web of Science ®Google Scholar
• Franchini M, Capra F, Targher G, et al. Relationship between ABO blood group and von Willebrand factor levels: from biology to clinical implications. Thromb J. 2007;5:14,9560-5-14.
   PubMedGoogle Scholar
• Fijnvandraat K, Peters M, ten Cate JW. Inter-individual variation in half-life of infused recombinant factor VIII is related to pre-infusion von Willebrand factor antigen levels. Br J Haematol. 1995;91:474–476.
   PubMed Web of Science ®Google Scholar
• Hazendonk HC, Lock J, Mathot RA, et al. Perioperative treatment of hemophilia A patients: blood group O patients are at risk of bleeding complications. J Thromb Haemost. 2015;14:468–478.
   Google Scholar
• Albanez S, Ogiwara K, Michels A, et al. Aging and ABO blood type influence VWF and FVIII levels through interrelated mechanisms. J Thromb Haemost. 2016;14:953–963.
   PubMed Web of Science ®Google Scholar
• Weiss HJ, Sussman II, Hoyer LW. Stabilization of factor VIII in plasma by the von Willebrand factor. Studies on posttransfusion and dissociated factor VIII and in patients with von Willebrand’s disease. J Clin Invest. 1977;60:390–404.
   PubMed Web of Science ®Google Scholar
• Konkle BA. Von Willebrand factor and aging. Semin Thromb Hemost. 2014;40:640–644.
   PubMed Web of Science ®Google Scholar
• Henrard S, Speybroeck N, Hermans C. Impact of being underweight or overweight on factor VIII dosing in hemophilia A patients. Haematologica. 2013;98:1481–1486.
   PubMed Web of Science ®Google Scholar
• Kawai R, Lemaire M, Steimer JL, et al. Physiologically based pharmacokinetic study on a cyclosporin derivative, SDZ IMM 125. J Pharmacokinet Biopharm. 1994;22:327–365.
   PubMedGoogle Scholar
• Kitchen S, Jennings I, Makris M, et al. Factor VIII assay variability in postinfusion samples containing full length and B-domain deleted FVIII. Haemophilia. 2016. doi:10.1111/hae.12962. [Epub ahead of print]
   Google Scholar
• Gruppo RA, Brown D, Wilkes MM, et al. Comparative effectiveness of full-length and B-domain deleted factor VIII for prophylaxis–a meta-analysis. Haemophilia. 2003;9:251–260.
   PubMed Web of Science ®Google Scholar
• Kreuz W, Ettingshausen CE, Zyschka A, et al. Inhibitor development in previously untreated patients with hemophilia A: a prospective long-term follow-up comparing plasma-derived and recombinant products. Semin Thromb Hemost. 2002;28:285–290.
   PubMed Web of Science ®Google Scholar
• Gouw SC, van der Bom JG, Auerswald G, et al. Recombinant versus plasma-derived factor VIII products and the development of inhibitors in previously untreated patients with severe hemophilia A: the CANAL cohort study. Blood. 2007;109:4693–4697.
   PubMed Web of Science ®Google Scholar
• Iorio A, Halimeh S, Holzhauer S, et al. Rate of inhibitor development in previously untreated hemophilia A patients treated with plasma-derived or recombinant factor VIII concentrates: a systematic review. J Thromb Haemost. 2010;8:1256–1265.
   PubMed Web of Science ®Google Scholar
• Harrison JF, Bloom AL, Abildgaard CF. The pharmacokinetics of recombinant factor VIII. The rFactor VIII clinical trial group. Semin Hematol. 1991;28:29,35; discussion 36.
   PubMed Web of Science ®Google Scholar
• Morfini M, Marchesini E, Paladino E, et al. Pharmacokinetics of plasma-derived vs. recombinant FVIII concentrates: a comparative study. Haemophilia. 2015;21:204–209.
   PubMed Web of Science ®Google Scholar
• Steele MR, Nagel K, Chan AK. Pharmacokinetics of recombinant and plasma-derived factor VIII products in paediatric patients with severe haemophilia A. Haemophilia. 2014;20:e100–e101.
   PubMed Web of Science ®Google Scholar
• George LA, Camire RM. Profile of efraloctocog alfa and its potential in the treatment of hemophilia A. J Blood Med. 2015;6:131–141.
   PubMedGoogle Scholar
• Ivens IA, Baumann A, McDonald TA, et al. PEGylated therapeutic proteins for haemophilia treatment: a review for haemophilia caregivers. Haemophilia. 2013;19:11–20.
   PubMed Web of Science ®Google Scholar
• Opar A. The clot thickens for long-lasting drugs that stop hemophilia short. Nat Med. 2013;19:121.
   Web of Science ®Google Scholar
• Peters RT, Toby G, Lu Q, et al. Biochemical and functional characterization of a recombinant monomeric factor VIII-Fc fusion protein. J Thromb Haemost. 2013;11:132–141.
   PubMed Web of Science ®Google Scholar
• Skotnicki A, Lissitchkov TJ, Mamonov V, et al. Efficacy, safety and pharmacokinetic profiles of a plasma-derived VWF/FVIII concentrate (VONCENTO(R)) in subjects with haemophilia A (SWIFT-HA study). Thromb Res. 2016;137:119–125.
   PubMed Web of Science ®Google Scholar
• Schulte S. Innovative coagulation factors: albumin fusion technology and recombinant single-chain factor VIII. Thromb Res. 2013;131(Suppl 2):S2–S6.
   PubMed Web of Science ®Google Scholar
• Zollner S, Raquet E, Claar P, et al. Non-clinical pharmacokinetics and pharmacodynamics of rVIII-SingleChain, a novel recombinant single-chain factor VIII. Thromb Res. 2014;134:125–131.
   PubMed Web of Science ®Google Scholar
• Neelakantan S, Li S, Powell J, et al. Population pharmacokinetic analysis of long-lasting recombinant factor VIII Fc fusion protein (rFVIIIFc) in patients with severe haemophilia A. J Thromb Haemost. 2013;11:354. Abstract PA 2.06-3.
   Web of Science ®Google Scholar
• Miners AH, Lee CA. Setting research priorities to improve cost-effectiveness estimations of primary prophylaxis with clotting factor for people with severe haemophilia. Haemophilia. 2004;10(Suppl 1):58–62.
   PubMed Web of Science ®Google Scholar
• Miners A. Revisiting the cost-effectiveness of primary prophylaxis with clotting factor for the treatment of severe haemophilia A. Haemophilia. 2009;15:881–887.
   PubMed Web of Science ®Google Scholar
• Johnson KA, Zhou ZY. Costs of care in hemophilia and possible implications of health care reform. Hematology Am Soc Hematol Educ Program. 2011;2011:413–418.
   PubMedGoogle Scholar
• Gringeri A, Wolfsegger M, Steinitz KN, et al. Recombinant full-length factor VIII (FVIII) and extended half-life FVIII products in prophylaxis–new insight provided by pharmacokinetic modelling. Haemophilia. 2015;21:300–306.
   PubMed Web of Science ®Google Scholar
• Shapiro AD, Ragni MV, Kulkarni R, et al. Recombinant factor VIII Fc fusion protein: extended-interval dosing maintains low bleeding rates and correlates with von Willebrand factor levels. J Thromb Haemost. 2014;12:1788–1800.
   PubMed Web of Science ®Google Scholar
• Berntorp E. Pharmacokinetics of plasma-derived and recombinant factor IX: using population pharmacokinetics with sparse sampling data needs further study. Haemophilia. 2013;19:805–807.
   PubMed Web of Science ®Google Scholar
• Fernandes S, Carvalho M, Lopes M, et al. Impact of an individualized prophylaxis approach on young adults with severe hemophilia. Semin Thromb Hemost. 2014;40:785–789.
   PubMed Web of Science ®Google Scholar
• Jayandharan GR, Srivastava A. The phenotypic heterogeneity of severe hemophilia. Semin Thromb Hemost. 2008;34:128–141.
   PubMed Web of Science ®Google Scholar
• Oldenburg J. Optimal treatment strategies for hemophilia: achievements and limitations of current prophylactic regimens. Blood. 2015;125:2038–2044.
   PubMed Web of Science ®Google Scholar
• Kempton CL, White GC 2nd. How we treat a hemophilia A patient with a factor VIII inhibitor. Blood. 2009;113:11–17.
   PubMed Web of Science ®Google Scholar